Significant advances in the understanding of the genetic abnormalities that lead to the development, progression, and metastasis of neoplastic diseases has raised the promise of gene therapy as an approach to medical intervention. Most of the clinical protocols that have been approved in the United States for gene therapy have used the viral vectors because of the high efficiency of gene transfer. Conventional means of gene delivery using viral vectors, however, has undesirable side effects such as insertion of mutational viral gene into the host genome and development of replication competent viruses. Among nonviral gene delivery methods, polymeric nanoparticles are increasingly becoming popular as vectors of choice. The major limitation of these nanoparticles is poor transfection efficiency at the target site after systemic administration due to uptake by the cells of reticuloendothelial system (RES). In order to reduce the uptake by the cells of the RES and improve blood circulation time, these nanoparticles are coated with hydrophilic polymers such as poly(ethylene glycol) (PEG). This article reviews the use of such hydrophilic polymers employed for improving the circulation time of the nanocarriers. The mechanism of polymer coating and factors affecting the circulation time of these nanocarriers will be discussed. In addition to the long circulating property, modifications to improve the target specificity of the particles and the limitations of steric protection will be analyzed.
Introduction
According to the reports from the World Health Organization, global cancer rates are expected to increase by 50% to a total of 15 million by the year 2020 (1). The funding of the United States National Cancer Institute to more than 5000 investigators world wide for their research in cancer indicates the importance of eliminating the suffering and death due to cancer (2). The progress of research in the area of cancer requires a new paradigm in diagnosis and therapy of the disease.
Although, chemotherapy has an important place in the clinical management of cancer, there are several limitations that require development of newer strategies for cancer therapy. Many of these drugs have narrow therapeutic indices resulting in high cytotoxicity to the surrounding healthy cells. Secondly, chemotherapeutic agents cannot be targeted to mutations affecting cell division, differentiation, and apoptosis. Gene therapy represents an interesting alternative where the protein of interest can be made locally near the disease site. The advantages of gene therapy include localized and sustained expression of genes in the target tissue, possibility of delivery of more than one transgene in the same vector, ability to treat drug resistant tumors, and low toxicity to the host.
Cancer is associated with abnormalities in the sequence and expression of some critical genes, namely the proto-oncogenes (oncogenes) and the tumor suppressor genes. Protooncogenes are converted to oncogenes by mutations or transformation and enhance cell proliferation. Tumor suppressor genes are the growth suppressors which function as antioncogenes, e.g., p53, pRB, BRCA, APC, et cetera. Therefore these anti-oncogenes can be used to treat cancer cells that are caused due to multiple genetic mutations (3, 4) . Based on the type of genes used in the treatment of cancer, gene therapy methods can be broadly classified into replacement of tumor suppressor genes, stimulation of the immune system, use of suicide gene therapy, and anti-angiogenic gene therapy (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The various gene based therapeutics under clinical trials and that are used for the treatment of cancer are listed in Table I (16) (17) (18) (19) (20) .
Tumor Physiology
Typically a tumor constitutes neoplastic cells, stromal cells and the extracellular matrix and is associated with blood vessels, nerves and immune cells that form an integral part of the stroma (21, 22) . Solid tumors are characterized by vasculature that is heterogeneous in size and distribution with center avascular necrotic region and vascularized peripheral region with discontinuous endothelium in the microvessels. Depending on the anatomic region of the tumor the pore size of the endothelial junctions is found to vary between 100 nm to 780 nm (23) (24) (25) (26) . This unique feature of leakiness along with the lack of lymphatic drainage is together termed as enhanced permeability and retention effect and is first studied in solid tumors by Maeda et al. using The tumor also contains leukocytes, fibroblasts, and other extracellular elements. Of the infiltrated leukocytes majority of them constitute macrophages which are more popu-larly referred to as tumor associated macrophages (TAM). These cells are located throughout the tumor including the ductal, stromal, and necrotic areas and were found to play an active role in tumor progression. TAM's are activated macrophages (M2) that have poor antigen presenting ability unlike the M1 macrophages that kill the tumor cell and present antigens to produce high levels of immunostimulatory cytokines. The TAM's or M2 macrophages are better adapted for phagocytic activity, help in repair of damaged tissues and promote angiogenesis. The presence of these activated macrophages in large numbers might lead to enhanced clearance of drug carrying vector from the tumor microenvironment (21, 22, 30, 31) .
Barriers for Delivery of Drugs and DNA to Tumors
For the delivery of drugs to the tumors, the vector used should carry the drug/DNA through the blood vessels to the tumor, transport it across the vessel walls into the surrounding tumor tissue and through the interstitial space within the tumor (25, 26) . The barriers also includes, uptake of the DNA by the cancerous cells, which is mostly endocytosis. Once inside the cells, the DNA has to escape the degradation by the "lytic" enzymes in the highly acidic environment of the endolysosomes, enter the nucleus through the pores present on the nuclear membrane and get integrated with the host genome machinery and express the gene of interest ( Figure  2 ). In addition to protecting the DNA from hydrolysis, the vector should protect it from degradation in the endolysosome in its enroute to the nucleus.
Naked DNA upon intravenous injection is rapidly degraded by the hydrolytic endo-and exo-nucleases. In gene delivery, the DNA used is more commonly a plasmid, which is supercoiled structure and exists as a particulate material with a net negative charge. The charge, large molecular weight, and poor stability of the DNA in the systemic circulation present a barrier to cellular uptake. The net negative charge due to the phosphate backbone of the DNA would result in an electrostatic repulsion from the negatively charged cell surface. For instance, naked DNA cannot cross barriers such as the gastrointestinal tract, keratinized epithelium, and the blood brain barrier. Hence in vivo gene therapy necessitates the formulation of DNA into vectors for targeting a specific population of cells either locally or systemically (32).
Vectors for Gene Delivery to Tumors
Gene delivery to target cells can be achieved by either viral or non-viral methods. Viral vectors such as adenoviruses, retroviruses, adeno-associated viruses (AAVs), lentivirus, and herpes simplex virus are generally used for transfection of the genes. Although efficient in transfection, these vectors are plagued by issues of integration with the host genome, selfreplication, recombination potential, and immunogenicity. There are reported incidents of insertional mutagenesis during treatment in humans and their safety is an issue (33, 34) . Viral vectors are relatively expensive to manufacture and have difficulties in bypassing the immune defense mechanism.
Among the non-viral vectors that are used for gene delivery to tumors there has been an enormous amount of research on cationic liposomes and lipoplexes (plasmid DNA-cationic lipid complexes). Cationic liposomes are bilayered vesicles that are prepared from cationic lipids that have a hydrophobic fatty acyl group and a positively charged head group. Some of the most commonly used cationic lipids include 2,3-bis(oleoyl)oxipropyltrimethylammonium chloride (DOTMA), 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), dioctadecyl amino glycyl spermine (DOGS) and 2,3 dioleyloxy-N-[2(spermine carboxaminino)ethyl]-N,Ndimethyl-1-propanaminium trifluoroacetate (DOSPA) (35). These systems were found to mediate transfection through the formation of an electrostatic complex between the positively charged liposomes and the negatively charged DNA that results in condensation of nucleic acids. The resulting complexes had a net positive charge that would promote interaction with the negatively charged cell surface. In addition, these cationic liposomal formulations were assumed to have fusogenic properties that would destabilize the plasma membrane and induce fusion that would facilitate intracellular release of the complexed DNA (35-37).
However, despite the fact that cationic liposomes have high transfection efficiency in vitro, owing to their toxicity and rapid clearance these formulations have limited efficiency in vivo. The cationic liposomes being positively charged, form aggregates with the negatively charged serum proteins and opsonins resulting in enhanced phagocytosis and clearance from the blood circulation. Based on the net charge on these complexes, they are accumulated to a greater extent in the lung followed by liver and spleen (38, 39) . Upon intravenous administration, these systems were found to be associated with dose dependent toxicity resulting in an increase in the serum levels of liver enzymes indicating hepatic necrosis (40). These cationic lipid-DNA complexes were also found to trigger immune response that is characterized by the release of proinflammatory cytokines such as IL-6, IL-12, TNF-α and IFN-γ (41). Using these liposomes, efficient encapsulation of small molecules has been achieved (42). However, encapsulation of macromolecules such as plasmids and production of particles of smaller diameter has always been a challenge.
Besides cationic lipids, cationic polymers have also been used for complexation with DNA (polyplexes). Polyplexes have been formed from a variety of polycations such as polylysine (pLL), polyethylenimines (PEI), galoctosyl-PLSP (a lysine/serine copolymer with PEG5000 at the Cterminus and 2-4% of the lysine amino side chains linked to galactose), TMAEM (poly [2-(trimethylammonio)ethyl methylcrylate chloride]), Ga-pOrn-mHA2 (poly(Lornithine) modified with galactose and a fusogenic peptide (mHA2), and PIA (polyionosinic acid) (38, (43) (44) (45) (46) . These Polyplexes are in the size range of 60-200 nm. Unfortunately, most of these polyplexes are cleared rapidly from the circulation, in < 10 min, and preferentially accumulate in the liver (43). It is clear that most of the polyplex systems do not exhibit the pharmacokinetic characteristics required for systemic delivery applications.
Apart from cationic polymers, several other natural and synthetic polymers have been used in preparing DNA encapsulated nanoparticles. Polymeric nanoparticles are increasingly popular owing to their advantages, such as small size, ease of production and administration. Several polymers have been investigated as vectors for gene delivery applications. There has been a fair amount of success in reducing immunogenicity and cytotoxicity with the concomitant enhancement in the efficiency of transfection with these polymers. Similar to cationic systems, polymeric nanoparticles too are cleared from the systemic circulation by the cells of reticuloendothelial system (RES).
Surface modification of the conventional nanoparticles with water-soluble polymers such as PEG or poly(ethylene oxide (PEO) can result in long-circulating nanoparticles. The hydrophilic nature of these surface modified particles reduces their binding capacity to proteins (opsonins) resulting in reduced uptake by the RES. The major outcome of modification with PEG or other hydrophilic flexible polymer is the significant increase in circulation time, the advantages of which include maintenance of optimal therapeutic concentration of drug in the blood after single administration of the drug carrier, increased probability of extravasation and retention of the colloidal carrier in areas of discontinuous endothelium, and enhancement in targetability of the system by use of a target specific ligand (47).
Surface Modification and Mechanism of Long Circulation
Surface modification of the polymeric nanoparticles can be achieved by grafting the hydrophilic polymer chain covalently on to the nanoparticle surface, or by adsorption or by blending the co-polymer with the hydrophobic matrix polymer prior to nanoparticle formation. PEG has been widely used for surface modification of polymeric nanoparticles, and the polymer has a general structure of HO-(CH 2 CH 2 O) n -CH 2 CH 2 -OH. The polymer has a polyether backbone that is chemically inert with terminal hydroxyl groups that can be activated for conjugation with different types of polymers and drugs. PEG is considered to be non-toxic and is approved by the United States Food and Drug Administration (FDA) for internal use in humans and is included in the inactive ingredients list for oral and parenteral applications (48). Besides hydrophilicity and flexibility, the PEG molecules have low toxicity and immunogenicity. It is non-biodegradable and, therefore, excreted mainly by the kidneys when the molecular weight is less than 10,000 Da. PEG is commercially available in a wide range of molecular weights up to 100,000 Da. The terminal hydroxyl groups of PEG can be modified to obtain derivatives that can react with an array of functional groups. PEG derivatives can be synthesized as linear or in branched configurations. Furthermore, the chemical derivatization of PEG can be used for site directed PEGylation of protein/peptide or molecule of interest. The list of PEG reagents which can be used for site directed PEGylation of molecules is depicted in Table II (49, 50) .
The protective action (Stealth® property) of PEG is mainly due to the formation of a dense, hydrophilic cloud of long polyethylene chains on the surface of the colloidal particle that reduces the hydrophobic interactions with the RES. The tethered/chemically anchored PEG chains can undergo spatial conformations, thus preventing the opsonization of particles by the RES of the liver and spleen and, hence, improving the circulation time of molecules/particles in the blood. The greater the flexibility of the polymer, the greater is the total number of possible conformations and transition from one conformation to the other (51-54).
The mechanism of steric hindrance by the PEG modified surface was explained by Antonsen et al. The water molecules form a structured shell through hydrogen bonding to the ether oxygens of PEG. The tightly bound water forms a hydrated film around the particle and repels the protein interactions ( Figure 3 ) (55). Furthermore, PEGylation may also increase the hydrodynamic size of the particle decreasing their clearance through the kidney, the renal filtration being dependent on the molecular mass and volume. This would ultimately result in an increase in circulation half-life of the particles (56, 57). The technology of PEGylation is already in use and some of products that are currently marketed are listed in Table III (58-62 ).
The size, molecular weight, and shape of the PEG fraction and the linkage used to connect it to the entity of interest determine the consequences of PEGylation in relation to protein adsorption and pharmacokinetics (like volume of distri-bution, circulation time, and renal clearance). When formulated into colloidal particles, the PEG density on the colloidal surface can be changed by using PEG of appropriate molecular weight (hence PEG chain length) and molar ratio (hence the grafting efficiency). Longer PEG chains offer greater steric influence around the colloidal entity -similar to increased grafting density with shorter PEG chains. Longer PEG chains may also collapse onto nanoparticle surface, thus providing a hydrophilic shield (63). Colloidal particles modified with 6.5 mol% PEG were found to have better circulation time (t 1/2 of 170 min) when compared to 2.5 mol% PEG (t 1/2 of 80 min). At lower mol% the branched derivatives of PEG have better half-lives when compared to the unbranched, however at mol% as high as 7 both the branched and unbranched derivatives have similar steric effect. The polymers with higher molecular weight and longer acyl anchor with higher energy of interaction were found to have effective steric protection (52, 64).
The major limitation of PEGylation is the possibility of decreased specificity. PEGylation leads to modification of the surface functional groups and there is a possibility of reduced association/interaction with the cells of interest. This might also lead to decrease in the transfection efficiency of the modified particles (56, 65).
Surface Modification Using Other Hydrophilic Polymers
Besides PEG, other hydrophilic polymers including poly(vinyl alcohol), poly(acryl amide), poly(vinylpyrrolidone), poly-[N-(2-hydroxypropyl)methacrylamide], polysorbate-80 (Tween® 80), and block co-polymers like poloxomer and poloxamine, are also being used to modify the Block co-polymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) have been widely used to modify the surface interactions of solid polymeric nanoparticles. The PPO forms the hydrophobic moiety, which is used as an anchor on the surface of the nanoparticles. Based on the composition and molecular weight of PEO and PPO, these amphipathic copolymers are commercially available as poloxamers and poloxamines (BASF Corporation, USA). The poloxamers, also called as Pluronics®, are triblock copolymers (PEO-PPO-PEO) and poloxamines (or Tetronics®) are tetrablock copolymers of PEO-PPO joined by a ethylene diamine bridge ((PEO-PPO) 2 -x-(PPO-PEO) 2 ) (68, 69).
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Natural Polymers
Gelatin: Gelatin is one of the most versatile, naturally occurring biopolymer that is used as a carrier for tumor targeted gene delivery applications. PEGylation of gelatin is carried out to improve drug performance by optimizing pharmacokinetics, increasing bioavailability, decreasing immunogenicity, and dosing frequency (70-75). In our lab, we have prepared PEG-modified gelatin for drug and DNA delivery applications. PEG-modified gelatin was synthesized by reacting type-B gelatin with PEG-epoxide (76).
It has been proved that PEGylated gelatin nanoparticles encapsulated with the plasmid pEGFP-N1 expressing green fluorescent protein had better transfection efficiency in mouse fibroblast cells (NIH3T3) when compared to the nanoparticles prepared from gelatin (77). The nanoparticles prepared from gelatin (Type-B) and PEGylated gelatin, were radiolabeled with iodine-125 ( 125 I) for in vivo biodistribution studies in mice bearing Lewis lung carcinoma (78) . From the radioactivity in plasma and various organs, it was evident that the majority of PEGylated nanoparticles were present either in the blood pool or taken up by the tumor mass and liver. For instance, after 3 h, the concentration of PEGylated gelatin nanoparticles was almost 2-fold higher in the blood pool than the control gelatin nanoparticles. PEGylated gelatin nanoparticles remained in the blood pool for a longer period of time due to the steric repulsion effect of the PEG chains as compared to the gelatin nanoparticles.
In addition, approximately 4-5% of the recovered dose of PEGylated gelatin nanoparticles was present in the tumor mass for up to 12 h. The plasma and the tumor half-lives, the mean residence time, and the area-under-the-curve of the PEGylated gelatin nanoparticles were significantly higher than those for the gelatin nanoparticles. In an other biodistribution study carried out by Kushibiki et al. using 125 I labeled nanoparticles, it was observed that PEGylated gelatin particles had increasing values of area under the curve (AUC) with increasing molecular weight of PEG grafted at the same degree of PEGylation with molecular weights of 12,000 being greater than 5000 and 2000 (79).
Chitosan: Chitosan is a biodegradable co-polymer of Nacteyl-D-glucosamine and D-glucosamine linked together by a β(1-4) glycosidic linkage. This natural polymer is used to prepare nanoparticles of size 100-250 nm by complex coecervation using sodium sulfate. Plasmid DNA (pREluciferase) encapsulated chitosan nanoparticles are prepared, that could protect the DNA from nuclease degradation. The researchers also conducted in vitro transfection studies using transferrin or KNOB protein conjugated chitosan nanoparticles which improved the transfection efficiency by 4-fold and 130-fold, respectively. The nanoparticles were also modified with succinimidyl succinimide of methoxy PEG (MSS-PEG) of molecular weight 5,000 Da to reduce clearance. The effect of PEGylation was apparent at lower time points (15min) with a 3-fold increase in the concentration of the radio labeled PEGylated chitosan nanoparticles when compared to the unmodified ones (80). These studies indicate the possibility of the usage of PEG modified chitosan nanoparticles for tumor targeted gene delivery applications, the targeting ability of which could be improved by conjugating with transferrin ligands.
Cyclodextrin and Cyclodextrin Polymers: Cyclodextrins (CyD) are oligosaccharides that are obtained by enzymatic modification of starch. Based on the number of oligomer units they are α, β or γ CyD's. The β-CyD's are the most widely studied, as they have the capacity to form inclusion complexes with various hydrophobic molecules (81). In addition to enhancing solublization and membrane penetration the CyD molecules also stabilize the nucleic acid molecules and prevent them from degradation from nucleases (82). Researchers have successfully developed a gene delivery system using CyD's to target tumor cells (83, 84). A nanoparticulate system has been prepared by condensation of cyclodextrin-nucleic acid complex and the surface of which is modified with PEG and a glycoprotein (transferrin). The iron binding glycoprotein, transferrin, is recognized by the transferrin receptors expressed on cell surface. Generally, the rapidly dividing cells such as the tumor cells that are in need of iron, express the transferrin receptor to a greater extent than the non-dividing cells. The transferrin conjugated particles are then taken up by cells by endocytosis, which results in dissociation of iron and recycling of transferrin to the cell surface. The in vitro experiments carried out using these particles are known to have shown greater transfection efficiency in K562 leukemia cells in comparison to non-targeted particles. These results are promising and indicate the possibility of their usage for systemic delivery of nucleic acid molecules in cancer therapy (85-87).
CyD based polymers have been synthesized by modifying cyclodextrin with polycations such as poly(amidoamine) dendrimers and poly(ethyleneimine). These polymers were found to have self-assembling and condensing property similar to that of cyclodextrin and increased transfection efficiency due to the polycations. These CyD polymers are further modified using adamantane PEG (AD-PEG) conjugates during the complexation process with nucleic acids.
The PEG modification has resulted in increased stability of the particle and reduction in surface charge (by using ADanionic-PEG) which would prevent aggregation and nonspecific cellular uptake. In vivo delivery of these PEG modified CyD polymeric particles to tumor cells is further enhanced by conjugating with transferrin (Tf-PEG-AD) (88). This was proven by injecting tumor bearing (PC-3, prostrate carcinoma cells that are p53 null and expressing transferrin receptor on cell surface) mice with Tf-PEG particles encapsulated with p53 gene (89).
Synthetic Polymers
Poly(lactide-co-glycolide) (PLGA): PLGA is a biocompatible and biodegradable polyester co-polymer of polylactic acid and polyglycolic acid, has been recognized for its ability to deliver genes. However, gene delivery by PLGA nanoparticles is limited by their negative charge and poor transport through mucosal barriers. A study has been reported, where PLGA nanoparticles have been surface modified with polyvinyl alcohol-chitosan or polyvinyl alcohol-chitosan-PEG. The nanoparticles were tested for their ability to transport genes in vivo in mice using nasal mucosa. The results indicated facilitated gene delivery and expression in vivo coupled with reduced toxicity (90).
Poly(alkylcyanoacrylates):
Poly(alkylcyanoacrylates) are biodegradable polymers, which are widely used for the delivery of anti-cancer drugs. One of the major advantages of using poly(alkylcyanoacrylates) is the ease of polymerization since the monomers do not require any energy for polymerization (91). The most widely used poly(alkylcyanoacrylates) are poly(butylcyanoacrylate) (PBCA), poly(hexylcyanoacrylate) (PHCA), poly(isohexylcyanoacrylate) (PIHCA), poly(isobutylcyanoacrylate) (PIBCA), and poly(methylcyanoacrylate) (PMCA). The molecular weight of these polymers, the residence time of the polymer in the plasma, as well as, biodegradation kinetics depends on the alkyl chain length (92). This was further proved by the experiments of Couvreur et al. that the heavier polymer (PHCA) would be cleared more slowly than the lighter one (PIBCA) (91). In a different study the researchers have synthesized PEG modified polycyanoacrylate nanoparticles in order to reduce their accumulation in liver. The nanoparticles were prepared by nanoprecipitation/ solvent diffusion using a pre-synthesized poly(methoxypolyethylene glycol cyanoacrylate-co-hexadecylcyanoacrylate) copolymer. These particles have reduced cytotoxicity in vitro and longer circulation time in vivo, which has been proved by injecting mice with particles radiolabeled with 14 C. Interestingly these particles were taken up by spleen, indicating a possibility of targeting to this tissue (93).
Polyamidoamine (PAMAM): PAMAM dendrimers are highly branched macromolecules with repeated units of polyamidoamine. These dendrimers have very high molecular uniformity and narrow weight distribution and are manufactured by repetitive steps which add twice the number of reactive sites and double the molecular weight. A new generation of polymers is synthesized with each step. The polymer has protonated amine groups that are responsible for condensation of DNA and used for endosmal buffering that helps in protecting the DNA from the lysosomal enzymes (94-96). The partially degraded high generation polymers of PAMAM (SuperFect®) are used to improve transfection efficiency and were found to be better than the regular lipid transfection agents. However, the partially degraded PAMAM dendrimer was found to be cytotoxic. The generation 5 PAMAM is conjugated with biocompatible PEG chains of molecular weight 3400 Da in order to lower its toxicity and enhance the transfection efficiency by 20-fold when compared to the unmodified dendrimer (97).
Modified Cationic Polymers
Poly(L-lysine)(pLL): As discussed earlier, in order to avoid the protein interaction and reduce uptake by macrophages in vivo, pLL polyplexes can be stabilized by PEGylation. It is observed that PEGylation did not effect the transfection efficiency of the polymer up to 60% the molecular weight fraction of PEG (98). Besides, the higher generation dendritic polymers of poly(L-lysine) (6 th generation, KG6) have higher transfection efficiency and stealth properties that enhance the circulation time (up to 3 h following intravenous injection) of the particles which resulted in entrapment of DNA complexes of the polymer in the tumor due to the EPR effect (99). pLL-DNA complex has also been coated with a multivalent hydrophilic polymer (poly[N-(2-hydroxypropyl)methacrylamide) (pHPMA). However, the coated polyplex had even shorter circulation lifetime than pLL/DNA complex. Attachment of a targeting ligand (transferrin) to pHPMA-pLL/DNA polypelx increased the trasfection of K562 cells some 15-fold, but in vivo studies have not been performed (67).
Poly(ethyleneimine) (PEI) is a cationic polymer that is used to form polyelectrolyte complexes with DNA. Due to its high transfection efficiency, the polymer is used in various cell culture experiments and gene delivery applications in vivo. The polymer has a pH buffering effect, due to which the complexed DNA escapes the endosomal degradation and gets integrated with the nucleus to express the transgene. One of the promising study examined the effect of PEGylating DNA/transferrin-PEI polyplex. The polyplexes were small (40 nm) and exhibited extended circulation times compared to non-PEGylated controls. Approximately 33% of the PEG-polyplex remained in the circulation after 30 min, while only 6% of the non-PEGylated polyplex remained in the circulation at that time. Both the polyplexes were capable of transfecting K562 and neuro-2a cells in vitro, but only the PEGylated polyplexes were able to trasfect a distal tumor following intravenous injection, employing a neuro-2 a mouse tumor model (100). The tumor targeting ability of these PEGylated polyplexes is further enhanced by conjugating with folate, epidermal growth factor and Arg-Gly-Asp (RGD) peptide (101-107).
Poly(dimethylaminomethyl methacrylate):
The polymer poly(dimethylaminomethyl methacrylate) (pDMAEMA) has been developed as a non-viral gene delivery vector. The cationic polymer is used to form complexes with DNA and the polyplexes formed are used to transfect cells in vitro. To improve its characteristics, the polymer is conjugated with PEG either by forming a block copolymer which is later used to prepare nanoparticles or by post-PEGylation wherein the PEG molecules are grafted on to the surface of the polyplexes formed from the complexation of DNA with the polymer pDMAEMA. In the studies carried out in vitro the particles prepared by both the PEGylation methods were found to be stable with the post-PEGylated particles having a better shielding effect from the serum components the highest effect observed with PEG of molecular weight 20,000 Da. Consequently, better circulation time and hence tumor accumulation have been associated with the post-PEGylated particles when injected into mice bearing subcutaneous tumors which amounted to 3.5% and 4.2% of the injected dose per gram of tumor tissue in Neuro2A and C26 tumors respectively (108).
In a different study by Stolnik and co-workers carried out in the cell lines A549, HepG2, and COS-7, it has been observed that PEG modification has actually resulted in a decrease in interaction and cellular internalization of the particles when compared to the DNA-polymer complexes. They have also observed the effect of molecular structure of the copolymers on the transfection efficiency with branched or bottle-brush type coplymers having still lower transfection efficiency than the linear ones (109). However, the binding ability polymer to antisense oligonucleotides was found to be better in case of the copolymers rather than the homopolymer of DMAEMA (110).
Moreover, the targeting efficiency of these surface modified nanoparticles can be further enhanced by conjugation with ligands/moieties like transferrin, folate, epidermal growth factor, and RGD peptide some of which have already been discussed above.
Conclusions
Completion of the Human Genome Project has lead to excitement in scientific arena about the implication of molecular medicine for systemic diseases such as cancer. The reason for the excitement was simple: most diseases have a genetic component and gene therapy holds the hope of curing, not merely treating, a broad range of aliments, including inherited diseases like cystic fibrosis and even chronic conditions like cancer, and infectious diseases like AIDS. While the expectations and the promise of therapy are great, clinical efficacy has not been definitely demonstrated at this point of time in any gene therapy protocol. Significant problems remain in all basic aspects of gene therapy. Major difficulties at the basic level include shortcomings in all current gene delivery methods and inadequate understanding of the biological interaction of these delivery vectors with the host.
Although the viral vectors are ideal carries, their use has been plagued by integration with the host genome, self-replication, and recombination potential. The use of non-viral vectors is becoming more appealing to the scientific community because of the availability of wide range of materials which can be engineered for delivery of genetic materials. Use of nanotechnology and advanced surface engineering techniques are expected to further contribute to the development of "nano" carriers for the delivery of the genes with targetability and long circulating properties.
